1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Gelesis Holdings, Inc.

Gelesis Holdings, Inc.

GLSHQ
Gelesis Holdings, Inc.US flagOther OTC
0.00
USD
- -
- -
7,334.00Market Cap
2021 Y
2022 Y
TTM
Revenue per Share
0.15
0.37
0.17
Basic EPS, GAAP
-1.3
-0.81
-0.71
Free Cash Flow per Basic Share
-1.04
-1.24
-0.69
Dividend per Share
- -
- -
- -
Book Value per Share
-3.68
-4.59
-4.59
Tangible Book Value per Share
-4.62
-0.37
-0.42
Basic Weighted Avg Shares
72
70
73
Sales/Revenue/Turnover
11
26
12
Operating Margin (%)
-759.7
-472.72
-546.48
Depreciation Expense
4
5
8
Net Income, GAAP
-94
-57
-52
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
-837.93
-221.71
-425.58
Working Capital
-3
-27
-26
LT Debt
37
26
28
Total Equity
-318
-12
-19
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
36
34
34
LT Borrowings
25
26
27
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
73
73
73
Market Capitalization
20
12
3

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
23
25
25
Cash, Cash Equivalents & STI
7
3
8
Accounts Receivable, Net
1
1
1
Inventories
7
6
6
Total Current Liabilities
51
49
50
Payables & Accruals
14
15
16
ST Debt
36
34
34
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-96.08%
Free Cash Flow
- -
- -
15.48%
Net Income, GAAP
- -
- -
-39.05%
Sales/Revenue/Turnover
- -
- -
130.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
11
2022
8
9
7
3
26
2023
2
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-1.3
2022
-0.09
-0.17
-0.2
- -
-0.81
2023
-0.07
-0.1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Alessandro Sannino
Full Time Employees
93
Sector
Healthcare
Industry
Biotechnology
Address
501 Boylston Street Boston MA United States of America 02116
IPO Date
Aug 24, 2020
CIK
0001805087
Website
gelesis.com
Similar Companies
NanoSphere Health Sciences Inc. (NSHSF)
ContraFect Corporation (CFRX)
Abcam plc (ABC.L)
MetaVia Inc. (MTVA)
Aerovate Therapeutics, Inc. (AVTE)
Aeglea BioTherapeutics, Inc. (AGLE)
Business
Gelesis Holdings, Inc. was a biotherapeutics firm that engaged in developing innovative biomimicry solutions for conditions such as excess weight and various gastrointestinal chronic illnesses. The company's flagship offering was PLENITY, an orally administered, non-systemic and non-stimulant preparation designed to aid in weight management. Additionally, Gelesis was actively progressing candidates like GS200 for addressing weight loss in individuals with prediabetes and type 2 diabetes, alongside GS500 for functional constipation. Early-stage investigations also included GS300, aimed at non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Founded in 2006, the company maintained its headquarters in Boston, Massachusetts. However, Gelesis Holdings, Inc., along with its affiliates, initiated a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware on October 30, 2023, ceasing all operations at that time. Subsequently, a Chapter 7 trustee was appointed, and substantially all of the company's assets, including its intellectual property, were sold in July 2024.